Company Contact:
Richard Gabriel
CEO and President
941 366-3400
-or-
Ron Stabiner
The Wall Street Group, Inc.
212-888-4848

FOR IMMEDIATE RELEASE:

DNAPRINT GENOMICS ANNOUNCES FIRST SCHEDULED SALES OF UPGRADED DNAWITNESS PRODUCT FEATURING RETINOME 2.0

Australian Laboratory Scheduled to Purchase New Kits; Improved Iris Color Detection, In-Laboratory Processing Are Latest Improvements

SARASOTA, Fla., August 10, 2006 – DNAPrint Genomics, Inc. (OTCBB: DNAG) today announced the first scheduled sales of its improved DNAWITNESS product incorporating several improvements made to the Retinome testing process, now called Retinome 2.0, which offers improved iris color detection and allows crime scene investigators to develop samples in their own laboratories.

A laboratory at the Victoria University School of Molecular Sciences in Melbourne, Australia, which performs work in collaboration with the Victoria Police Forensic Science Service (VPFSS), is scheduled to purchase the first Retinome 2.0 kits under an International Science Linkages grant from the Australian Government's Department of Education, Science and Technology.

"The upgrades to DNAWITNESS feature several improvements, including proprietary processes that offer greater precision and enhanced value," stated DNAPrint President and Chief Executive Officer Richard Gabriel. "We are pleased that the forensics laboratory at Victoria University has chosen to purchase these kits, and we look forward to providing more of them in the future to Australian authorities and to law enforcement officials worldwide."

Retinome 2.0 is an improved version of Retinome 1.0, a test developed from the Company's continued research on the genetics of human iris color. The new version includes additional patent-pending markers covering newly identified and informative regions of the human pigmentation gene OCA2. Retinome 1.0 will be discontinued in favor of the newly improved version of the test.

In addition, the Company has also developed a Retinome 2.0 capillary electrophoresis kit, which permits investigators to test Retinome 2.0 in their own laboratories, obviating the need to ship their samples to DNAPrint (though that option is still available).

Since early 2005, the Company has been offering Retinome 1.0 as part of its DNAWITNESS package in order to test for iris color. DNAWITNESS employs patent pending database-driven methods to infer elements of physical appearance from crime scene DNA (www.dnawitness.net) and allow forensic investigators to "paint" molecular portraits from crime scene DNA.

About DNAPrint Genomics, Inc.

DNAPrint Genomics, Inc. (www.dnaprint.com) is a developer of genomics-based products and services in two primary markets: biomedical and forensics. DNAPrint Pharmaceuticals, Inc., a wholly owned subsidiary, develops diagnostic tests and theranostic products (drug/test

(MORE)

combinations) using the Company's proprietary ancestry-informed genetic marker studies combined with proprietary computational modeling technology. Computational Biology and Pharmacogenomics services are also offered externally to biopharmaceutical companies. The Company's first theranostic product is PT-401, a "Super EPO" (erythropoietin) dimer protein drug for treatment of anemia in renal dialysis patients (with end stage renal disease). Preclinical and clinical development of all the Company's drug candidates will benefit from simulated pre-trials to design actual trials better and are targeted to patients with genetic profiles indicating their propensity to have the best clinical responses. DNAPrint is proud of its continued dedication to developing and supplying new technological advances in law enforcement and consumer ancestry heritage interests. Please refer to www.dnaprint.com for information on law enforcement and consumer applications which include DNAWITNESS(TM), RETINOME(TM), ANCESTRYbyDNA(TM) and EURO-DNA(TM). DNAWitness-Y and DNAWitness-Mito are two tests offered by the Company. The results from these tests may be used as identification tools when a DNA sample is deteriorated or compromised or other DNA testing fails to yield acceptable results.

Forward-Looking Statements

All statements in this press release that are not historical are forward-looking statements. Such statements are subject to risks and uncertainties that could cause actual results to differ materially from those projected, including, but not limited to, uncertainties relating to technologies, product development, manufacturing, market acceptance, cost and pricing of DNAPrint's products, dependence on collaborations and partners, regulatory approvals, competition, intellectual property of others, and patent protection and litigation. DNAPrint Genomics, Inc. expressly disclaims any obligation or undertaking, except as may be required by applicable law or regulation to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in DNAPrint's expectations with regard thereto or any change in events, conditions, or circumstances on which any such statements are based.

##